Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2024/01/062079
CTRI/2024/01/062079
Not yet recruiting
Phase 1

A study to investigate the antiretroviral drug in Ayurveda. - Nill

Satyananda yoga and Ayurveda Research institute Motihari0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Satyananda yoga and Ayurveda Research institute Motihari
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Satyananda yoga and Ayurveda Research institute Motihari

Eligibility Criteria

Inclusion Criteria

  • •Patients diagnosis to be HIV Positive

Exclusion Criteria

  • •Taking immunomodulatory
  • •Patient of antiretroviral Therapy
  • •Pregnancy or lactation

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Essai pilote évaluant un traitement antirétroviral associant le MK-0518, le darunavir/ritonavir (TMC114/r) et l’etravirine (TMC125) chez les patients infectés par le VIH-1, en échec virologique et porteurs de virus multi-résistants. - TRIO
EUCTR2007-000670-23-FRAgence nationale de recherches sur le sida et les hépatites virales. ANRS
Completed
Not Applicable
Directly Observed antiretroviral Therapy for people living with Human Immunodeficiency Virus (HIV) and Acquired ImmunDeficiency Syndrome (AIDS): a randomised controlled trial
ISRCTN48682427Ministry of Health (Brazil)
Completed
Not Applicable
A clinical trial of R-CHOP with antiretroviral therapy for newly diagnosed CD20 positive AIDS-related non-Hodgkin lymphomaewly diagnosed CD20 positive AIDS-related non-Hodgkin lymphoma
JPRN-UMIN000001452AIDS Clinical Center42
Active, not recruiting
Phase 1
Initiation of first-line antiretroviral treatment with TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the first clinical contact in France: Trial IMEA 055 – FASTHIV positive age > 18 years -newly diagnosed HIV-infected individual evidenced by any tests -antiretroviral-treatment naive -negative urine pregnancy test -willing to sign an informed written consent– -regular health insurance -willing to provide two distinct contact information (telephone number and/or email) in order to be easily reached if needed between Day 0 and Day 7Therapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2019-000812-27-FRIMEA110
Recruiting
Not Applicable
igeria PrEP Demonstration StudyHIV/AIDS
PACTR201605001602542ational Agency for the Control of AIDS600